Cite
HARVARD Citation
Pai, V. et al. (n.d.). A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). Journal of diabetes science and technology. pp. 132-141. [Online].